Swertia chirayita ameliorates MAFLD by improving intestinal microenvironment and hepatic lipogenesis - PubMed
3 days ago
- #MAFLD
- #Swertia chirayita
- #gut microbiota
- Swertia chirayita (SC) shows therapeutic effects on Metabolic-associated fatty liver disease (MAFLD).
- SC improves intestinal microenvironment and hepatic lipogenesis in MAFLD rats.
- SC administration reduces fat accumulation, insulin resistance, and improves liver enzyme activities.
- It enhances gut microbiota diversity and restores microbial community composition.
- SC increases beneficial short-chain fatty acids (SCFAs) and strengthens gut barrier function.
- The herb regulates bile acid metabolism and inhibits hepatic lipogenesis via BAs/FXR/FGF15 and SHP/SREBP-1c pathways.
- SC demonstrates potential as a natural remedy for MAFLD by targeting multiple mechanisms.